Evidence map›Paper›PMID 25419594›Full record

Trial reportJournal of pediatric gastroenterology and nutrition2014

Total serum bilirubin predicts fat-soluble vitamin deficiency better than serum bile acids in infants with biliary atresia.

Veena L Venkat, Benjamin L Shneider, John C Magee, Yumirle Turmelle, Ronen Arnon, Jorge A Bezerra, Paula M Hertel, Saul J Karpen, Nanda Kerkar, Kathleen M Loomes and 13 more

Registry-linked trialOpen access · greenAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of pediatric gastroenterology and nutrition, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03499249 (A Phase 2 Trial of N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03499249 phase2completednot on this mapstarted 2018, after this paper: background citation

A Phase 2 Trial of N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy

TypeinterventionalSponsorBaylor College of MedicineRan2018 to 2024Enrolled13ConditionsBiliary AtresiaArmsN-Acetyl cysteine
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Review
  7. Adjuvant treatments for biliary atresia.Translational pediatrics · 2020
    Review
  8. Article
  9. Bile Acids as Metabolic Regulators and Nutrient Sensors.Annual review of nutrition · 2019 · on this map
    Review
  10. Observational
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 18 institutions in 2 countries.

Veena L Venkat*Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA †Department of Surgery and Department of Biostatistics, University of Michigan, Ann Arbor, MI ‡Department of Pediatrics, Washington University, St Louis, MO §Department of Pediatrics, Mount Sinai Medical Center, New York, NY ||Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH ¶Department of Pediatrics, Texas Children's Hospital, Houston #Department of Pediatrics, Children's Health Care of Atlanta, Atlanta, GA **Department of Gastroenterology, Children's Hospital Los Angeles, Los Angeles, CA ††Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA ‡‡Department of Pediatrics, Riley Children's Hospital, Indianapolis, IN §§Department of Pediatrics, Seattle Children's Hospital, Seattle, WA ||||Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada ¶¶School of Public Health, University of Michigan, Ann Arbor ##Department of Pediatrics, University of California San Francisco, San Francisco ***Department of Pediatrics, Johns Hopkins University, Baltimore †††National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD ‡‡‡Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora §§§Department of Pediatrics, Saint Louis University School of Medicine, St Louis, MO ||||||Department of Pediatric Surgery, Children's Hospital Los Angeles, Los Angeles, CA ¶¶¶Department of Pediatrics, Children's Memorial Hospital, Chicago, IL.
Benjamin L Shneider
John C Magee
Yumirle Turmelle
Ronen Arnon
Jorge A Bezerra
Paula M Hertel
Saul J Karpen
Nanda Kerkar
Kathleen M Loomes
Jean Molleston
Karen F Murray
Vicky L Ng
Trivellore Raghunathan
Philip Rosenthal
Kathleen Schwartz
Averell H Sherker
Ronald J Sokol
Jeffrey Teckman
Kasper Wang
Peter F Whitington
James E Heubi
Childhood Liver Disease Research and Education Network
Children's Hospital of Pittsburgh · USCincinnati Children's Hospital Medical Center · USUniversity of Michigan–Ann Arbor · USChildren's Healthcare of Atlanta · USChildren's Hospital Colorado · USChildren's Hospital of Philadelphia · USHospital for Sick Children · CALurie Children's Hospital · USMount Sinai Medical Center · USNational Institutes of Health · USRiley Hospital for Children · USSaint Louis University · USSeattle Children's Hospital · USSouthern California University for Professional Studies · USTexas Children's Hospital · USUniversity of California, San Francisco · USUniversity of Southern California · USWashington University in St. Louis · US

Funding

Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
Institute of Translational Health SciencesUL1TR000423 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$49.4M
Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
Institutional Clinical and Translational Science AwardUL1TR000003 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2015
$38.9M
Childhood Liver Disease Research Network Data Coordinating CenterU01DK062456 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MAGEE, JOHN C, MERION, ROBERT M · 2002 to 2019
$36.8M
Southern California Clinical and Translational Science InstituteUL1TR000130 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BUCHANAN, THOMAS A · 2012 to 2015
$36.0M
UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Stem Cell/Organoid and Genome Editing CoreP30DK078392 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI Kathryn Ann Wikenheiser-Brokamp · 2007 to 2026
$24.4M
Colorado Clinical and Translational Science Institute (UL1)UL1TR000154 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2012 to 2013
$20.4M
NCATS NIH HHS UL1 TR000003NCATS NIH HHS UL1TR000003NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1TR000004NCATS NIH HHS UL1 TR000005NCATS NIH HHS UL1TR000005NCATS NIH HHS UL1 TR000006NCATS NIH HHS UL1TR000006NCATS NIH HHS UL1 TR000077NCATS NIH HHS UL1TR000077NCATS NIH HHS UL1 TR000130NCATS NIH HHS UL1TR000130NCATS NIH HHS UL1 TR000150NCATS NIH HHS UL1TR000150NCATS NIH HHS UL1 TR000154NCATS NIH HHS UL1TR000154NCATS NIH HHS UL1 TR000423NCATS NIH HHS UL1TR000423NCATS NIH HHS UL1TR000424NCATS NIH HHS UL1 TR000448NCATS NIH HHS UL1TR000448NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1TR000454NCATS NIH HHS UL1 TR001082NIDDK NIH HHS DK62436NIDDK NIH HHS DK62445NIDDK NIH HHS DK62452NIDDK NIH HHS DK62453NIDDK NIH HHS DK62466NIDDK NIH HHS DK62470NIDDK NIH HHS DK62481NIDDK NIH HHS DK62497NIDDK NIH HHS DK62500NIDDK NIH HHS DK62503NIDDK NIH HHS DK84536NIDDK NIH HHS DK84538NIDDK NIH HHS DK84575NIDDK NIH HHS P30 DK026743NIDDK NIH HHS P30 DK078392NIDDK NIH HHS U01 DK062436NIDDK NIH HHS U01 DK062445NIDDK NIH HHS U01 DK062452NIDDK NIH HHS U01 DK062453NIDDK NIH HHS U01 DK062456NIDDK NIH HHS U01 DK062466NIDDK NIH HHS U01 DK062470NIDDK NIH HHS U01 DK062481NIDDK NIH HHS U01 DK062497NIDDK NIH HHS U01 DK062500NIDDK NIH HHS U01 DK062503NIDDK NIH HHS U01 DK084536NIDDK NIH HHS U01 DK084538NIDDK NIH HHS U01 DK084575NIDDK NIH HHS U01 DK103135NIDDK NIH HHS U01 DK103149
6 · The paper itself

Abstract

objectiveFat-soluble vitamin (FSV) deficiency is a well-recognized consequence of cholestatic liver disease and reduced intestinal intraluminal bile acid. We hypothesized that serum bile acid (SBA) would predict biochemical FSV deficiency better than serum total bilirubin (TB) level in infants with biliary atresia.

methodsInfants enrolled in the Trial of Corticosteroid Therapy in Infants with Biliary Atresia after hepatoportoenterostomy were the subjects of this investigation. Infants received standardized FSV supplementation and monitoring of TB, SBA, and vitamin levels at 1, 3, and 6 months. A logistic regression model was used with the binary indicator variable insufficient/sufficient as the outcome variable. Linear and nonparametric correlations were made between specific vitamin measurement levels and either TB or SBA.

resultsThe degree of correlation for any particular vitamin at a specific time point was higher with TB than with SBA (higher for TB in 31 circumstances vs 3 circumstances for SBA). Receiver operating characteristic curve shows that TB performed better than SBA (area under the curve 0.998 vs 0.821). Including both TB and SBA did not perform better than TB alone (area under the curve 0.998).

conclusionsWe found that TB was a better predictor of FSV deficiency than SBA in infants with biliary atresia. The role of SBA as a surrogate marker of FSV deficiency in other cholestatic liver diseases, such as progressive familial intrahepatic cholestasis, α-1-antitrypsin deficiency, and Alagille syndrome in which the pathophysiology is dominated by intrahepatic cholestasis, warrants further study.

Indexed as

AvitaminosisBile Acids and SaltsBiliary AtresiaBilirubinDietary SupplementsDouble-Blind MethodFemaleHumansInfantInfant, NewbornMaleNational Institute of Diabetes and Digestive and Kidney Diseases (U.S.)PlacebosProspective StudiesUnited StatesVitamin ABile Acids and SaltsBilirubinPlacebosVitamin AVitamin DVitamin EVitamin KVitamins

Identifiers

PMID25419594
PMCPMC4243585
OpenAlexW2108544522

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.